Renaissance Technologies - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 289 filers reported holding BIO-TECHNE CORP in Q3 2017. The put-call ratio across all filers is 1.04 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$17,584
+169.9%
258,326
+223.7%
0.03%
+233.3%
Q2 2023$6,514
-80.9%
79,800
-82.6%
0.01%
-80.0%
Q1 2023$34,105
-1.6%
459,700
+9.9%
0.04%
-4.3%
Q4 2022$34,677
-100.0%
418,400
+54.4%
0.05%
-56.9%
Q3 2022$76,948,000
+51.8%
270,944
+85.3%
0.11%
+81.7%
Q2 2022$50,679,000
+262.3%
146,200
+352.6%
0.06%
+275.0%
Q1 2022$13,987,000
+193.8%
32,300
+251.1%
0.02%
+166.7%
Q4 2021$4,760,000
+263.9%
9,200
+240.7%
0.01%
+200.0%
Q3 2021$1,308,000
-66.2%
2,700
-68.6%
0.00%
-60.0%
Q2 2021$3,872,000
-71.6%
8,600
-75.9%
0.01%
-70.6%
Q1 2021$13,617,000
-73.8%
35,652
-78.3%
0.02%
-70.2%
Q4 2020$52,066,000
-33.0%
163,963
-47.7%
0.06%
-26.9%
Q3 2020$77,657,000
-24.6%
313,475
-19.7%
0.08%
-12.4%
Q2 2020$103,034,000
+11.6%
390,175
-19.9%
0.09%
-1.1%
Q1 2020$92,311,000
-16.9%
486,820
-3.8%
0.09%
+5.9%
Q4 2019$111,105,000
+0.1%
506,151
-10.8%
0.08%
-9.6%
Q3 2019$110,968,000
+12.7%
567,120
+20.1%
0.09%
+8.0%
Q2 2019$98,474,000
+1.2%
472,320
-3.7%
0.09%
-2.2%
Q1 2019$97,353,000
+8.3%
490,320
-21.1%
0.09%
-9.2%
Q4 2018$89,903,000
-0.7%
621,220
+40.0%
0.10%
+5.4%
Q3 2018$90,564,000
-22.7%
443,700
-43.4%
0.09%
+45.3%
Q2 2018$117,152,000
+109.5%
784,100
+111.7%
0.06%
+4.9%
Q1 2018$55,930,000
+21.3%
370,300
+4.0%
0.06%
+19.6%
Q4 2017$46,120,000
+55.9%
356,000
+45.5%
0.05%
+45.7%
Q3 2017$29,582,000
+71.2%
244,700
+66.3%
0.04%
+59.1%
Q2 2017$17,284,000
-9.8%
147,100
-22.0%
0.02%
-18.5%
Q1 2017$19,171,000
+2.7%
188,600
+3.9%
0.03%
-10.0%
Q4 2016$18,664,000
+18.8%
181,500
+26.5%
0.03%
+7.1%
Q3 2016$15,713,000
+250.1%
143,500
+260.6%
0.03%
+211.1%
Q2 2016$4,488,000
-54.4%
39,800
-61.8%
0.01%
-52.6%
Q1 2016$9,840,000
-31.6%
104,100
-34.9%
0.02%
-38.7%
Q4 2015$14,382,000
-36.6%
159,800
-34.9%
0.03%
-42.6%
Q3 2015$22,690,000
+17.9%
245,400
+25.6%
0.05%
+22.7%
Q2 2015$19,241,000
-31.8%
195,400
-30.5%
0.04%
-26.7%
Q1 2015$28,192,000
-42.1%
281,100
-46.6%
0.06%
-48.7%
Q4 2014$48,667,000526,7000.12%
Other shareholders
BIO-TECHNE CORP shareholders Q3 2017
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders